Skip to content

A clinical trial to assess the role of repetitive Transcranial Magnetic Stimulation (rTMS) in Smoking Cessation in an Egyptian Sample

A clinical trial to assess the role of repetitive Transcranial Magnetic Stimulation (rTMS) in Smoking Cessation in an Egyptian Sample

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
PACTR
Registry ID
PACTR202006900365423
Enrollment
54
Registered
2020-06-29
Start date
2019-08-01
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mental and Behavioural Disorders

Interventions

Sham repetitive Transcranial Magnetic Stimulation

Sponsors

Ain Shams University Institute of Psychiatry
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Both genders Ages 18 to 60 years. Current smokers or waterpipe users. Meet criteria for nicotine dependence as determined by the FTND. Willing to provide informed consent. Able to comply with protocol requirements and willing to complete all study procedures.

Exclusion criteria

Exclusion criteria: Current dependence, defined by ICD-10 criteria, on any psychoactive substances other than nicotine or caffeine or received substance use treatment within past 30 days History of serious mental illness such as: Bipolar disorder, Psychotic illness, Major Depression with psychotic features and other psychiatric illness such as OCD or eating disorders Contraindication to rTMS (history of neurological disorder or seizure, increased intracranial pressure, brain surgery, or History of autoimmune, endocrine, viral, or vascular disorder affecting the brain. History or MRI evidence of neurological disorder that would lead to local or diffuse brain lesions or significant physical impairment. Unstable cardiac disease, uncontrolled hypertension, severe renal or liver insufficiency.

Design outcomes

Primary

MeasureTime frame
Point prevalence of abstinence to be defined as a self-report of no smoking or other tobacco use (or other nicotine product use during the treatment phases) in the previous 7 days

Secondary

MeasureTime frame
Time to first relapse as defined by self-report after tobacco quit date AND end of rTMS sessions

Countries

Egypt

Contacts

Public ContactMayar Nawara

Assistant Lecturer of Psychiatry in department of Neuropsychiatry Ain Shams University Faculty of Medicine

mayar_nawara@med.asu.edu.eg+201227201306

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Feb 4, 2026